2. Academic Validation
  3. SKI-349, a Sphingosine Kinases 1/2 Inhibitor, Suppresses Cell Viability, Invasion, and AKT/mTOR Signaling Pathway, and Shows Synergistic Cytotoxic Effects with Sorafenib in Hepatocellular Carcinoma

SKI-349, a Sphingosine Kinases 1/2 Inhibitor, Suppresses Cell Viability, Invasion, and AKT/mTOR Signaling Pathway, and Shows Synergistic Cytotoxic Effects with Sorafenib in Hepatocellular Carcinoma

  • Tohoku J Exp Med. 2023 Dec 21. doi: 10.1620/tjem.2023.J100.
Liqiao Chen 1,  Liangliang Wang 1,  Zongqi Han 1,  Peng Qin 2,  Guangxu Niu 3,  Jingxia Du 1
Affiliations

Affiliations

  • 1 Department of Basic Medical, Xingtai Medical College.
  • 2 Department of Vascular Intervention, The Second Affiliated Hospital of Xingtai Medical College.
  • 3 Department of Pathology, Handan Central Hospital.
PMID: 38123304 DOI: 10.1620/tjem.2023.J100
Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-162143
    99.58%, SPHK1/2/MDA Inhibitor